A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease targeting the alveolar gas exchange apparatus, leading to death by asphyxiation. IPF progresses on a tissue scale through aberrant matrix remodeling, enhanced cell contraction, and subsequent microenvironment densification. Although two ph...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIP Publishing LLC
2021-12-01
|
| Series: | APL Bioengineering |
| Online Access: | http://dx.doi.org/10.1063/5.0054967 |
| _version_ | 1798034766662991872 |
|---|---|
| author | Katherine A. Cummins Peter B. Bitterman Daniel J. Tschumperlin David K. Wood |
| author_facet | Katherine A. Cummins Peter B. Bitterman Daniel J. Tschumperlin David K. Wood |
| author_sort | Katherine A. Cummins |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease targeting the alveolar gas exchange apparatus, leading to death by asphyxiation. IPF progresses on a tissue scale through aberrant matrix remodeling, enhanced cell contraction, and subsequent microenvironment densification. Although two pharmaceuticals modestly slow progression, IPF patient survival averages less than 5 years. A major impediment to therapeutic development is the lack of high-fidelity models that account for the fibrotic microenvironment. Our goal is to create a three-dimensional (3D) platform to enable lung fibrosis studies and recapitulate IPF tissue features. We demonstrate that normal lung fibroblasts encapsulated in collagen microspheres can be pushed toward an activated phenotype, treated with FDA-approved therapies, and their fibrotic function quantified using imaging assays (extracellular matrix deposition, contractile protein expression, and microenvironment compaction). Highlighting the system's utility, we further show that fibroblasts isolated from IPF patient lungs maintain fibrotic phenotypes and manifest reduced fibrotic function when treated with epigenetic modifiers. Our system enables enhanced screening due to improved predictability and fidelity compared to 2D systems combined with superior tractability and throughput compared to 3D systems. |
| first_indexed | 2024-04-11T20:48:54Z |
| format | Article |
| id | doaj.art-19c7b835430d42d488c0ad731d4140d7 |
| institution | Directory Open Access Journal |
| issn | 2473-2877 |
| language | English |
| last_indexed | 2024-04-11T20:48:54Z |
| publishDate | 2021-12-01 |
| publisher | AIP Publishing LLC |
| record_format | Article |
| series | APL Bioengineering |
| spelling | doaj.art-19c7b835430d42d488c0ad731d4140d72022-12-22T04:03:54ZengAIP Publishing LLCAPL Bioengineering2473-28772021-12-0154046102046102-1210.1063/5.0054967A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosisKatherine A. Cummins0Peter B. Bitterman1Daniel J. Tschumperlin2David K. Wood3 Department of Biomedical Engineering, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USA Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota 55902, USA Department of Biomedical Engineering, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, USAIdiopathic pulmonary fibrosis (IPF) is a lethal lung disease targeting the alveolar gas exchange apparatus, leading to death by asphyxiation. IPF progresses on a tissue scale through aberrant matrix remodeling, enhanced cell contraction, and subsequent microenvironment densification. Although two pharmaceuticals modestly slow progression, IPF patient survival averages less than 5 years. A major impediment to therapeutic development is the lack of high-fidelity models that account for the fibrotic microenvironment. Our goal is to create a three-dimensional (3D) platform to enable lung fibrosis studies and recapitulate IPF tissue features. We demonstrate that normal lung fibroblasts encapsulated in collagen microspheres can be pushed toward an activated phenotype, treated with FDA-approved therapies, and their fibrotic function quantified using imaging assays (extracellular matrix deposition, contractile protein expression, and microenvironment compaction). Highlighting the system's utility, we further show that fibroblasts isolated from IPF patient lungs maintain fibrotic phenotypes and manifest reduced fibrotic function when treated with epigenetic modifiers. Our system enables enhanced screening due to improved predictability and fidelity compared to 2D systems combined with superior tractability and throughput compared to 3D systems.http://dx.doi.org/10.1063/5.0054967 |
| spellingShingle | Katherine A. Cummins Peter B. Bitterman Daniel J. Tschumperlin David K. Wood A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis APL Bioengineering |
| title | A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis |
| title_full | A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis |
| title_fullStr | A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis |
| title_full_unstemmed | A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis |
| title_short | A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis |
| title_sort | scalable 3d tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis |
| url | http://dx.doi.org/10.1063/5.0054967 |
| work_keys_str_mv | AT katherineacummins ascalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis AT peterbbitterman ascalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis AT danieljtschumperlin ascalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis AT davidkwood ascalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis AT katherineacummins scalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis AT peterbbitterman scalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis AT danieljtschumperlin scalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis AT davidkwood scalable3dtissueculturepipelinetoenablefunctionaltherapeuticscreeningforpulmonaryfibrosis |